Cortechs.ai obtained expanded EU medical device certification for its NeuroQuant platform, enabling automated quantitative imaging across neurology, neuro-oncology, and prostate analysis. The certification validates a scalable framework for AI-driven tissue volumetry and longitudinal tracking in clinical practice across the European Economic Area.
Key Points
- EU CE marking expansion covers five product modules including brain tumor and prostate imaging
- Automated segmentation and volumetric analysis enable longitudinal tracking of tissue changes
- Certification positions platform for international expansion and future neuro-oncology applications
Longevity Analysis
Quantitative imaging that tracks volumetric changes in brain tissue and related structures over time provides objective biomarkers for neurodegeneration and disease progression—data that would otherwise remain subjective or visual. This capability shifts assessment from qualitative observation to measurable trajectories, enabling earlier detection of pathological changes and more precise monitoring of intervention effects. For clinicians and researchers, automated volumetric analysis reduces interpretation variability and creates standardized datasets suitable for longitudinal studies, directly supporting the ability to decode meaningful signals from imaging data and track whether specific interventions are producing measurable effects on tissue structure.
Original published by LT Wire.